Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 15, 2025

Primary Completion Date

June 15, 2026

Study Completion Date

August 15, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Biweekly 5-FLUOROURACIL (5-FU)

5-FU 2400 mg/m². Infusion for 46 hours. Leucovorin 200 mg/m². Either a vascular endothelial growth factor (VEGF) inhibitor or epidermal growth factor (EGFR) inhibitor or may be added to the regimen at the discretion of the treating physician. Repeat every 2 weeks.

DRUG

Biweekly Modified FOLFOX6

Oxaliplatin 85 mg/m². 5-FU 400 mg/m² on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m² Infusion for 46 hours. Leucovorin 200 mg/m2. Repeat every 2 weeks

DRUG

Biweekly FOLFIRI

"Irinotecan 180 mg/m2. 5-FU 400 mg/m2 on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m2 Infusion for 46 hours. Leucovorin 200 mg/m2.~Repeat every 2 weeks."

DRUG

mFOLFOXIRI

Irinotecan 165 mg/m2. Oxaliplatin 85 mg/m2. 5-FU 2400 mg/m2 Infusion for 46 hours. Repeat every 2 weeks.

Trial Locations (1)

22042

Inova Health Care Service, Falls Church

Sponsors
All Listed Sponsors
lead

Inova Health Care Services

OTHER